Samsung Biologics signs largest manufacturing deal with Asia-based pharmaceutical company

INCHEON, South Korea, Oct. 21, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced today a contract manufacturing deal with an Asia-based pharmaceutical company. The disclosed deal, worth USD 1.24 billion,...